Journal article
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Abstract
PurposeAnthracyclines are frequently used in adjuvant treatment for early-stage breast cancer (ESBC). The purpose of this study was to evaluate cardiotoxic effects in the first five years after treatment with different anthracycline-based regimens.MethodsCCTG MA.21 (NCT000142) was a phase III trial in ESBC that compared cyclophosphamide (75 mg/m2) orally for 14 days, epirubicin (60 mg/m2) and fluorouracil, IV days one and eight (CEF) for six …
Authors
Dent SF; Botros J; Rushton M; Aseyev O; Levine MN; Parulekar WR; O’Brien P; Burnell M; Pritchard KI; Chen BE
Journal
Breast Cancer Research and Treatment, Vol. 184, No. 3, pp. 733–741
Publisher
Springer Nature
Publication Date
12 2020
DOI
10.1007/s10549-020-05887-w
ISSN
0167-6806